North Bengal Oncology Centre Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 24-10-2024
- Paid Up Capital ₹ 4.97 Cr
as on 24-10-2024
- Company Age 21 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 14.83 Cr
as on 24-10-2024
- Revenue 34.46%
(FY 2023)
- Profit 154114.70%
(FY 2023)
- Ebitda 10712.11%
(FY 2023)
- Net Worth 87.68%
(FY 2023)
- Total Assets 55.95%
(FY 2023)
About North Bengal Oncology Centre
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 4.97 Cr.
The company has closed loans amounting to ₹14.83 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Ayanabh Debgupta and Saumitra Bharadwaj serve as directors at the Company.
- CIN/LLPIN
U85110WB2003PTC096386
- Company No.
096386
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Jun 2003
- Date of AGM
28 Jun 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Darjiling, West Bengal, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at North Bengal Oncology Centre?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Saumitra Bharadwaj  | Director | 19-Jan-2015 | Current |
| Ayanabh Debgupta | Director | 10-Apr-2023 | Current |
Financial Performance of North Bengal Oncology Centre.
North Bengal Oncology Centre Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 34.46% increase. The company also saw a substantial improvement in profitability, with a 154114.7% increase in profit. The company's net worth Soared by an impressive increase of 87.68%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of North Bengal Oncology Centre?
In 2023, North Bengal Oncology Centre had a promoter holding of 75.93% and a public holding of 24.07%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Yes Bank Limited Creation Date: 30 Nov 2015 | ₹8.50 Cr | Satisfied |
Corporation Bank Creation Date: 23 Mar 2005 | ₹6.33 Cr | Satisfied |
How Many Employees Work at North Bengal Oncology Centre?
North Bengal Oncology Centre has a workforce of 2 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of North Bengal Oncology Centre, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped North Bengal Oncology Centre's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
